Loading…
for educational and safety purposes
1V-LSD and 1B-LSD both come up in the same conversations; they overlap on Serotonin. 1V-LSD: 1V-LSD (1-valeroyl-LSD), nicknamed "Valerie," is an N1-acylated lysergamide that can be regarded as a higher homolog of ALD-52, 1P-LSD, and 1B-LSD, marketed as a research chemical. 1B-LSD: 1B-LSD (1-butyryl-LSD) is a semisynthetic lysergamide bearing a four-carbon butyryl group on the indole nitrogen of lysergic acid diethylamide, distributed as a research chemical.
1V-LSD (1-valeroyl-LSD), nicknamed "Valerie," is an N1-acylated lysergamide that can be regarded as a higher homolog of ALD-52, 1P-LSD, and 1B-LSD, marketed as a research chemical. In the mouse head-twitch response it acts as a dose-dependent psychedelic with a median effective dose of about 373 nmol/kg, roughly one third the potency of LSD, and like related N1-acyl lysergamides it is believed to be hydrolyzed in vivo to LSD, functioning as a prodrug that engages the 5-HT2A receptor. It has been characterized by extensive mass spectrometry, chromatography, and spectroscopy, and has been identified in seized blotter products in Japan. In silico toxicology has additionally flagged the strongest predicted hERG channel inhibition of its series, suggesting comparatively higher theoretical proarrhythmic potential.
1B-LSD (1-butyryl-LSD) is a semisynthetic lysergamide bearing a four-carbon butyryl group on the indole nitrogen of lysergic acid diethylamide, distributed as a research chemical. Pharmacological and biotransformation studies of 1-acyl-substituted LSD derivatives indicate that N1-acylation sharply lowers direct affinity and efficacy at 5-HT2A and related serotonin receptors, yet these compounds still evoke the head-twitch response in mice because they are rapidly deacylated in vivo to LSD; this supports classification of 1B-LSD as a prodrug. Once cleaved, the liberated LSD produces the characteristic serotonergic psychedelic state through 5-HT2A receptor agonism. Analytical and in silico toxicological work has since characterized its mass-spectral fingerprint, serum deacylation, and predicted organ-toxicity profile alongside related N1-acyl lysergamides.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
partial agonist (via LSD)
partial agonist (via LSD)
agonist
agonist
partial agonist
partial agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.